Publication: Prevalence of HIV-1 subtypes and antiretroviral drug resistance mutations in nepal
Issued Date
2016-12-01
Resource Type
ISSN
18734251
1570162X
1570162X
Other identifier(s)
2-s2.0-84995945046
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current HIV Research. Vol.14, No.6 (2016), 517-524
Suggested Citation
Nirajan Bhusal, Ruengpung Sutthent, Navin Horthongkham, Niracha Athipanyasilp, Wannee Kantakamalakul Prevalence of HIV-1 subtypes and antiretroviral drug resistance mutations in nepal. Current HIV Research. Vol.14, No.6 (2016), 517-524. doi:10.2174/1570162X14666161003141950 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/40783
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Prevalence of HIV-1 subtypes and antiretroviral drug resistance mutations in nepal
Other Contributor(s)
Abstract
© 2016 Bentham Science Publishers. Background: There have been very few reports of HIV-1 subtypes and drug resistance mutations (DRMs) from Nepal which is geographically located between two high-prevalence HIV-1 infection countries, China and India. Objective: The aim of this study was to determine prevalence of acquired and transmitted DRMs and HIV-1 subtypes in Nepal. Methods: Thirty-five HIV-1 seropositive samples from central region of Nepal were collected in 2011. The subjects were divided into two groups, antiretroviral (ARV) drug naïve group (n=15) and antiretroviral treatment (ART) group (n=20), 90% (18/20) of them received zidovudine, lamivudine and nevirapine (AZT/3TC/NVP) regimen. HIV pol (protease and reverse transcriptase regions) nucleotide sequences were analyzed by Viroseq HIV-1 Genotyping System. Nearly full-length genomic (NFLG) sequences of 10 samples were performed. Results: NFLG genotyping revealed that 80% of samples were infected with subtype C and 20% with recombinants (C/D/H and C/A). Phylogenetic analysis of 35 pol sequences from Nepal were subtype C. The prevalence of acquired DRMs to NNRTIs and NRTIs was 15% (3/20). DRMs to NVP, K103N and V179D, and to NRTIs were observed at 11.1% (2/18) and 5% (1/20), respectively. The prevalence of DRMs to rilpivirine for E138A/G was 5.7%. The minor protease inhibitors (PI) associated mutations (A71T/V and T74S) were observed in 5/35 (14.3%) subjects. Conclusion: This is the first report of NFLG HIV-1 genomic sequences and DRMs from Nepal. National surveillance of HIV DRMs to ARVs and molecular epidemiology study should be done annually for better prevention and treatment of HIV infection in Nepal.